ArticleScientific reports2025
Supraspan memory performance is impaired in subjective cognitive impairment compared to cognitively unimpaired individuals.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The associations between ATN biomarkers and episodic memory diminish as age increases.European geriatric medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective cognitive status is incompletely known in Subjective Cognitive Impairment (SCI) and similar constructs. To characterize subspan and supraspan memory performance in groups with SCI, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired individuals (CU) in relation to brain atrophy and CSF biomarkers. Performance on subspan (Digit Span Forward) and supraspan memory (trial 1 in the Rey Auditory Verbal Learning test) was investigated in patients diagnosed with SCI (n = 237) and MCI (n = 1038) from memory clinics in the Stockholm region and CU individuals from Stockholm university, Department of Psychology (n = 124). All participants had an extensive cognitive assessment. In addition, MCI and SCI patients had a comprehensive clinical examination, brain imaging scan (medial temporal lobe, cortical global atrophy, and white-matter-hyperintensities), and CSF biomarker analyses (Abeta, p-tau, and total-tau). Groups differed significantly in demographic characteristics, which were adjusted for in all analyses. The three groups differed significantly on supraspan, but not subspan, memory performance in line with the severity of cognitive impairment. The test-by-group interaction was also significant showing that SCI was characterized by selective supraspan impairment in conjunction with memory overload and in contrast to the previous conception of no objective impairment in SCI. CSF biomarkers and brain abnormality in MTA, GCA, and WMH did not provide additional predictive power over the diagnostic group on supraspan in SCI. Supraspan memory performance differed by diagnostic group in relation to the degree of cognitive impairment in memory clinic participants (CU > SCI > MCI) indicating objective memory impairment in SCI interpreted as due to supraspan overload.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.